Literature DB >> 16750367

The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.

Mark Sabat1, John C Vanrens, Michael P Clark, Todd A Brugel, Jennifer Maier, Roger G Bookland, Matthew J Laufersweiler, Steven K Laughlin, Adam Golebiowski, Biswanath De, Lily C Hsieh, Richard L Walter, Marlene J Mekel, Michael J Janusz.   

Abstract

A series of C-2, C-8, and N-9 trisubstituted purine based inhibitors of TNF-alpha production are described. The most potent analogs showed low nanomolar activity against LPS-induced TNF-alpha production in a THP-1 cell based assay. The SAR of the series was optimized with the aid of X-ray co-crystal structures of these inhibitors bound with mutated p38 (mp38).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750367     DOI: 10.1016/j.bmcl.2006.05.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.

Authors:  Angela S Carlson; Huarui Cui; Anand Divakaran; Jorden A Johnson; Ryan M Brunner; William C K Pomerantz; Joseph J Topczewski
Journal:  ACS Med Chem Lett       Date:  2019-08-02       Impact factor: 4.345

2.  Identification of potential TNF-α inhibitors: from in silico to in vitro studies.

Authors:  Komal Zia; Sajda Ashraf; Almas Jabeen; Maria Saeed; Mohammad Nur-E-Alam; Sarfaraz Ahmed; Adnan J Al-Rehaily; Zaheer Ul-Haq
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

3.  Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.

Authors:  D Martin Watterson; Valerie L Grum-Tokars; Saktimayee M Roy; James P Schavocky; Brinda Desai Bradaric; Adam D Bachstetter; Bin Xing; Edgardo Dimayuga; Faisal Saeed; Hong Zhang; Agnieszka Staniszewski; Jeffrey C Pelletier; George Minasov; Wayne F Anderson; Ottavio Arancio; Linda J Van Eldik
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.